May, B., Conway, N., Truong, T., Linhart, S., Smitherman, C., March, L., … Secord, A. A. (2025). FRα, B7-H4, and HER2 expression in endometrial cancer: Assessing the promise of antibody drug conjugate therapies. In Gynecologic Oncology (Vol. 200, pp. S3–S3). Elsevier BV. https://doi.org/10.1016/j.ygyno.2025.04.523

May, Bobby, Nicholas Conway, Tracy Truong, Sarah Linhart, Carson Smitherman, Lauren March, Andrew Berchuck, Haley Moss, Brittany Davidson, and Angeles Alvarez Secord. “FRα, B7-H4, and HER2 expression in endometrial cancer: Assessing the promise of antibody drug conjugate therapies.” In Gynecologic Oncology, 200:S3–S3. Elsevier BV, 2025. https://doi.org/10.1016/j.ygyno.2025.04.523.

May B, Conway N, Truong T, Linhart S, Smitherman C, March L, et al. FRα, B7-H4, and HER2 expression in endometrial cancer: Assessing the promise of antibody drug conjugate therapies. In: Gynecologic Oncology. Elsevier BV; 2025. p. S3–S3.

May, Bobby, et al. “FRα, B7-H4, and HER2 expression in endometrial cancer: Assessing the promise of antibody drug conjugate therapies.” Gynecologic Oncology, vol. 200, Elsevier BV, 2025, pp. S3–S3. Crossref, doi:10.1016/j.ygyno.2025.04.523.

May B, Conway N, Truong T, Linhart S, Smitherman C, March L, Berchuck A, Moss H, Davidson B, Secord AA. FRα, B7-H4, and HER2 expression in endometrial cancer: Assessing the promise of antibody drug conjugate therapies. Gynecologic Oncology. Elsevier BV; 2025. p. S3–S3.